Safety of high-dose nicotinamide: a review

@article{Knip2000SafetyOH,
  title={Safety of high-dose nicotinamide: a review},
  author={M. Knip and I. Douek and W. P. Moore and H. A. Gillmor and A. E. Mclean and P. Bingley and E. Gale and for the Endit Group},
  journal={Diabetologia},
  year={2000},
  volume={43},
  pages={1337-1345}
}
  • M. Knip, I. Douek, +5 authors for the Endit Group
  • Published 2000
  • Medicine
  • Diabetologia
  • Abstract Nicotinamide, the amide derivative of nicotinic acid, has over the past forty years been given at high doses for a variety of therapeutic applications. It is currently in trial as a potential means of preventing the onset of Type I (insulin-dependent) diabetes mellitus in high-risk, first-degree relatives. Nicotinamide is for regulatory purposes classed as a food additive rather than a drug and has not therefore required the formal safety evaluation normally expected of a new therapy… CONTINUE READING

    Paper Mentions

    INTERVENTIONAL CLINICAL TRIAL
    Nicotinamide is an inhibitor of human sirtuins (HDAC III), and is found to re-activate epigenetically silenced tumor suppressors, RUNX3 (runt-related gene 3) and others, in cancer… Expand
    ConditionsNon-Small-Cell Lung Carcinoma
    InterventionDrug
    INTERVENTIONAL CLINICAL TRIAL
    The purpose of this study is to assess an effective single oral supplement or combination of oral supplements for increasing whole blood NAD+ levels.  
    ConditionsIncrease in Blood Levels of Nicotinamide Adenine Dinucleotide (NAD+)
    InterventionDietary Supplement